SCHEMBL3012937

SCHEMBL3012937

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.41
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 3/20 0.39
MAPT P10636 4/20 0.39
TSHR P16473 2/20 0.39
F2 P00734 1/20 0.38
F2RL3 Q96RI0 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
LMNA P02545 3/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
KDM1A O60341 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPK1 P28482 1/20 0.36
FKBP1A P62942 1/20 0.36
FKBP4 Q02790 1/20 0.36
FKBP5 Q13451 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004189 0.93 MAPT (0.38) HTR7SMN1; SMN2RAB9AALDH1A1MAPT
SCHEMBL3009020 0.92 USP2 (0.41) HTR7SMN1; SMN2RAB9AALDH1A1MAPT
SCHEMBL3014222 0.91 MAPT (0.43) HTR7SMN1; SMN2RAB9AALDH1A1MAPT
SCHEMBL3014450 0.90 KDM4E (0.41) SMN1; SMN2RAB9AALDH1A1MAPTF2RL3
SCHEMBL3006248 0.90 DRD2 (0.36) HTR7SMN1; SMN2RAB9AMAPTFKBP1A
SCHEMBL3016542 0.90 TP53 (0.41) SMN1; SMN2RAB9AALDH1A1MAPTMEN1
SCHEMBL3010954 0.90 KCNQ1 (0.42) SMN1; SMN2RAB9AALDH1A1MAPTTSHR
SCHEMBL3023516 0.89 MAPT (0.42) SMN1; SMN2RAB9AALDH1A1MAPTTSHR
SCHEMBL3007183 0.89 ERBB2 (0.39) HTR7SMN1; SMN2RAB9AALDH1A1MAPT
SCHEMBL3017082 0.89 GAA (0.40) HTR7SMN1; SMN2RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HTR7 1836/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.